Drug Trial Radar · NCT03784014
Molecular Profiling of Advanced Soft-tissue Sarcomas
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
603
Actual
Start
Oct 19, 2019
Primary completion
Dec 1, 2023
Study completion Jan 20, 2026
Sponsor
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Commissariat A L'energie Atomique; Institut Bergonié; Plateforme labellisée Inca - Institut Bergonié, Bordeaux; Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris; EUCLID Clinical Trial Platform
- First posted
- Dec 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MULTISARC is a randomized multicenter study assessing whether high throughput molecular analysis (next generation sequencing exome - NGS) is feasible in advanced/metastatic soft-tissue sarcoma patients, that is, whether NGS can be conducted for a large proportion of patients, with results available within reasonnable delays. In parallel, MULTISARC aims to assess efficacy of an innovative treatment strategy guided by high throughput molecular analysis (next generation sequencing exome, RNASeq \[NGS\]) in patients with Advanced/metastatic soft-tissue sarcomas. At the end of first-line treatment, participant's tumor profile of experimental Arm NGS (treatment strategy based on NGS results) will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant. Participants for whom a targetable genomic alteration has been identified will be proposed to enter in one of the subsequent phase II single-arm sub-trial.
Conditions
- Soft Tissue Sarcoma
Interventions
NilotinibDrug
Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
CeritinibDrug
Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
CapmatinibDrug
Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
LapatinibDrug
Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
TrametinibDrug
Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
Trametinib and DabrafenibCombination product
Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
Olaparib and DurvalumabCombination product
Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
PalbociclibDrug
Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
GlasdegibDrug
Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
TAS-120Drug
Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
Next Generation sequencing exomeOther
Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the feasibility of high throughput molecular analysis (next generation sequencing exome [NGS]Time frame: 7 weeks
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Institut Bergonie
Bordeaux, France
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Institut de Cancérologie de Montpellier
Montpellier, France
Centre Antoine Lacassagne
Nice, France
Hôpital Cochin
Paris, France
Hôpital Pitié Salpétrière
Paris, France
Institut Curie
Paris, France
CHU Poitiers
Poitiers, France
Centre Eugène Marquis
Rennes, France
Centre Henri Becquerel
Rouen, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau
Saint-Herblain, France
ICANS - Institut de Cancérologie Strasbourg
Strasbourg, France
IUCT Oncopôle
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.